Circulating micrornas as novel minimally invasive biomarkers for breast cancer

Annals of Surgery

Volumn 251, Issue 3, 2010, Pages 499-505

  Heneghan, Helen M ^a   Miller, Nicola ^a   Lowery, Aoife J ^a   Sweeney, Karl J ^b   Newell, John ^a   Kerin, Michael J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LET 7A; MICRORNA; MICRORNA 10B; MICRORNA 145; MICRORNA 155; MICRORNA 16; MICRORNA 195; MICRORNA 21; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD; BLOOD SAMPLING; BREAST CANCER; CANCER SURGERY; CIRCULATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMALLY INVASIVE PROCEDURE; PLASMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77649138141     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181cc939f     Document Type: Article

References (27)

1. Taplin S, Abraham L, Barlow WE, et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst. 2008;100:876-887.
2. Thompson A, Brennan K, Cox A, et al. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res. 2008;10:R26.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
4. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312. (Pubitemid 350232263)
5. O'Hanlon DM, Kerin MJ, Kent P, et al. An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer. 1995;71:1288-1291.
6. Uehara M, Kinoshita T, Hojo T, et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol. 2007;13:447-451.
7. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838.
8. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065-7070.
9. Mattie MD, Benz CC, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5:24.
10. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007;29:36.
11. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672-675.
12. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513-10518.
13. Gilad S, Meiri E, Yogev Y, et al. Serum MicroRNAs are promising novel biomarkers. PLoS One. 2008;3:e3148.
14. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997-1006.
15. Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009;112:55-59.
16. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA. 2009;106:4402-4407.
17. Lowery AJ, Miller N, McNeill RE, et al. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res. 2008;14:360-365.
18. Davoren PA, McNeill RE, Lowery A, et al. Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol. 2008;9:76.
19. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008;18:505-516.
20. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189-198.
21. Brueckner B, Stresemann C, Kuner R, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 2007;67:1419-1423.
22. Chin LJ, Slack FJ. A truth serum for cancer-microRNAs have major potential as cancer biomarkers. Cell Res. 2008;18:983-984.
23. Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14:2348-2360.
24. Wickramasinghe NS, Manavalan TT, Dougherty SM, et al. Estradiol down-regulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 2009;37:2584-2595.
25. Ma L, Teruva-Feldstein J, Weinberg RA. Tumor invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682-1668
26. Qian B, Katsaros D, Lu L, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat. 2008;117:131-140.
27. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer. 2007; 109:1721-1728.